Every 10-Q that Xeris Biopharma Holdings (XERS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow XERS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XERS filings page.
Xeris Biopharma reported strong top-line growth for the quarter ended June 30, 2026, with total revenue $92.1 million versus $71.5 million a year earlier, driven mainly by Recorlev, whose net product revenue rose to $56.8 million for the quarter and $106.5 million year‑to‑date.
Higher volumes and improved product mix lifted income from operations to $5.2 million for the quarter and $13.1 million year‑to‑date, while cost of goods sold fell to 13.3% of product revenue for the first half. A $30.8 million loss on extinguishment of 2028 Convertible Notes, however, led to a quarterly net loss of $31.1 million and a first‑half net loss of $28.9 million, with stock‑based compensation of $15.2 million in the first half.
Cash and cash equivalents were $121.7 million at June 30, 2026, against total debt of $252.6 million and a stockholders’ deficit of $9.7 million. Management expects existing cash and cash flows to fund operations for at least 12 months while advancing XP‑8121 and managing ongoing Hatch‑Waxman patent litigation over Recorlev.
Xeris Biopharma Holdings reported a strong turnaround for the quarter ended March 31, 2026, moving to net income of $2.2 million from a net loss of $9.2 million a year earlier. Total revenue rose to $83.1 million from $60.1 million, driven mainly by Recorlev.
Recorlev net product revenue nearly doubled to $49.8 million, while Gvoke was stable at $20.8 million and Keveyis grew modestly to $11.9 million. Cost of goods sold grew more slowly than revenue, improving gross margin. Operating income reached $7.9 million, supported by higher sales despite increased selling and R&D spending.
Xeris ended the quarter with cash, cash equivalents and restricted cash of $115.8 million and generated $9.9 million of operating cash flow. Long‑term debt remained significant at $221.2 million, including 2028 Convertible Notes and 2029 term loans, and the company continues to invest in its XP‑8121 pipeline and platform partnerships.
Xeris Biopharma reported stronger Q3 results. Total revenue reached $74.380 million (up 37.1% year over year), led by Recorlev $36.975 million, Gvoke $25.151 million, and Keveyis $11.937 million. Operating income was $6.731 million versus a loss a year ago, and net income was $621 thousand.
For the first nine months, revenue was $206.038 million with a net loss of $10.527 million. Cost discipline and mix improved gross costs: cost of goods sold fell to 14.8% of product revenue in Q3 from 25.7% a year earlier, aided by fewer inventory write-offs.
Cash and cash equivalents were $91.598 million and total cash, cash equivalents and restricted cash were $95.619 million. Net debt stood at $219.469 million (including $33.6 million of 2028 convertible notes and $188.045 million of 2029 loans). Stockholders’ equity (deficit) improved to $(0.861) million from $(29.615) million at year-end. Management believes cash resources are sufficient for at least the next 12 months, while noting ongoing net losses and market risks.